<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03571425</url>
  </required_header>
  <id_info>
    <org_study_id>180509/B/03</org_study_id>
    <nct_id>NCT03571425</nct_id>
  </id_info>
  <brief_title>The Impact of Enteral Versus Oral Protein Feeding on Muscle Protein Synthesis in Healthy Young Males and Females</brief_title>
  <official_title>The Impact of Enteral Versus Oral Protein Feeding on Muscle Protein Synthesis in Healthy Young Males and Females</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Exeter</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Exeter</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study will seek to quantify the muscle protein synthetic response to a protein
      beverage consumed orally or through a nasogastric tube in healthy, young individuals.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thirty healthy, young volunteers will receive a stable isotope tracer infusion (8.5h)
      combined with repeated blood and muscle sampling, in order to measure muscle protein
      synthesis rate in the postabsorptive state, and following oral placebo ingestion (n=10), oral
      protein ingestion (n=10), or enteral protein administration (n=10).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 4, 2018</start_date>
  <completion_date type="Actual">December 1, 2018</completion_date>
  <primary_completion_date type="Actual">December 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Oral conditions are double blinded to participant and investigator, but enteral vs oral feeding is not blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Postprandial muscle protein synthesis</measure>
    <time_frame>5 hours</time_frame>
    <description>Muscle protein synthesis rate (FSR) following ingestion of a placebo or protein supplement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postabsorptive muscle protein synthesis</measure>
    <time_frame>2 hours</time_frame>
    <description>Muscle protein synthesis rate (FSR, in %/h) during a 2 hour fasting period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole-body protein synthesis</measure>
    <time_frame>7 hours</time_frame>
    <description>Whole-body protein synthesis, measured using a D5 phenylalanine and D2 tyrosine infusion (umol Phenylalanine/kg/h)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole-body protein breakdown</measure>
    <time_frame>7 hours</time_frame>
    <description>Whole-body protein breakdown, measured using a D5 phenylalanine and D2 tyrosine infusion (umol Phenylalanine/kg/h)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole-body protein oxidation</measure>
    <time_frame>7 hours</time_frame>
    <description>Whole-body protein oxidation, measured using a D5 phenylalanine and D2 tyrosine infusion (umol Phenylalanine/kg/h)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole-body protein net balance</measure>
    <time_frame>7 hours</time_frame>
    <description>Whole-body protein net balance, measured using a D5 phenylalanine and D2 tyrosine infusion (umol Phenylalanine/kg/h)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastric emptying rate</measure>
    <time_frame>5 hours</time_frame>
    <description>Gastric emptying rate following ingestion of a placebo or protein drink</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood glucose concentration</measure>
    <time_frame>8.5 hours</time_frame>
    <description>Blood glucose concentration in the postabsorptive and postprandial phase following placebo/protein ingestion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum insulin concentration</measure>
    <time_frame>8.5 hours</time_frame>
    <description>Serum insulin concentration in the postabsorptive and postprandial phase following placebo/protein ingestion</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Oral Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo drink</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Protein</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Protein drink, ingested orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enteral Protein</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Protein drink, administered via enteral tube</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oral Placebo</intervention_name>
    <description>A placebo beverage will be consumed orally</description>
    <arm_group_label>Oral Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oral Protein</intervention_name>
    <description>A protein beverage will be consumed orally</description>
    <arm_group_label>Oral Protein</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Enteral Protein</intervention_name>
    <description>A protein beverage will be consumed via a naso-gastric feeding tube</description>
    <arm_group_label>Enteral Protein</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-40 years of age

          -  Body mass index between 18.5 and 30

        Exclusion Criteria:

          -  Any diagnosed metabolic impairment (e.g. type 1 or 2 Diabetes)

          -  Any diagnosed cardiovascular disease

          -  Elevated blood pressure at the time of screening. (An average systolic blood pressure
             reading of ≥140 mmHg over two or more measurements and an average diastolic blood
             pressure of ≥90 mmHg over two or more measurements)

          -  Chronic use of any prescribed or over the counter pharmaceuticals (that may modulate
             muscle protein metabolism). This excludes oral contraceptives and contraceptive
             devices.

          -  A personal or family history of epilepsy, seizures or schizophrenia.

          -  Presence of an ulcer in the stomach or gut and/or strong history of indigestion

          -  Known pre-existing liver disease/condition

          -  Any known disorders in muscle metabolism

          -  Regular use of nutritional supplements

          -  Allergy to lidocaine

          -  Allergy to milk

          -  Current paracetamol use (i.e. use of paracetamol more than once a week)

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marlou Dirks, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Exeter</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Exeter</name>
      <address>
        <city>Exeter</city>
        <state>Devon</state>
        <zip>EX1 2LU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>May 24, 2018</study_first_submitted>
  <study_first_submitted_qc>June 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2018</study_first_posted>
  <last_update_submitted>December 19, 2018</last_update_submitted>
  <last_update_submitted_qc>December 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

